Investor relations

With the marketing approval for Sedaconda (isoflurane) in 15 EU countries and a great interest in inhaled sedation and our products, Sedana Medical is well-positioned for the future.

We are well on the way to the vision of making inhaled sedation a standard therapy in critical care.

The Share

See More

Press Releases

Invitation to presentation of Sedana Medical’s interim report for the third quarter 2022


Sedana Medical AB (publ) plans to present its interim report for the third quarter 2022 in an audioc…

Sedana Medical’s products receive MDR certification


Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announces that the company has received Medica…

Sedana Medical AB Interim report January-June 2022


Committed to change the standard of care, with commercial progress and a strong balance sheet.

View All Press Releases

Financial Calendar

Interim report Q3 2022 25 October 2022 07:00

See More